Clinical Trial Update: A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating FE 201836 for nocturia due to nocturnal polyuria in adults has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nocturia

Drugs mentioned

• FE 201836

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Nocturia | Phase 2 | Status: COMPLETED | Results posted: 2020-12-23